$1.81
-0.08-4.23%
Last update: Oct 30, 6:39 PM
Pyxis Oncology Inc (PYXS) Stock Price, Quote, News & History
PYXSNASDAQ
Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.
You can purchase shares of Pyxis Oncology (NASDAQ:PYXS) through any online brokerage.
Other companies in Pyxis Oncology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Pyxis Oncology has a consensus price target of $8.80.
The stock price for Pyxis Oncology (NASDAQ: PYXS) is $1.87 last updated October 30, 2026 at 6:39 PM EDT.
There are no upcoming dividends for Pyxis Oncology.
Pyxis Oncology does not have any upcoming earnings scheduled.
There is no upcoming split for Pyxis Oncology.
Pyxis Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly...
